Literature DB >> 16353169

Lack of genetic and epigenetic changes in meningiomas without NF2 loss.

Angela A G van Tilborg1, Bruno Morolli, Micheline Giphart-Gassler, Annie de Vries, Daniëlle A N van Geenen, Irene Lurkin, Johan M Kros, Ellen C Zwarthoff.   

Abstract

Approximately 60% of sporadic meningiomas are caused by inactivation of the NF2 tumour suppressor gene. The causative gene for the remaining meningiomas is unknown. Previous studies have shown that these tumours have no recurrent karyotypic abnormalities. They differ from their NF2-related counterparts in that they are more often of the meningothelial subtype and are located preferentially in the anterior skull base. To gain more insight into the aetiology of these tumours, we studied genetic and epigenetic alterations in 25 meningiomas without NF2 involvement. We first established a genome-wide allelotype using 3 microsatellite markers per chromosome arm. Loss of heterozygosity (LOH) was detected at a low frequency and no indication for the location of putative tumour suppressor genes could be established. We next screened the subtelomeric regions by using 2-3 polymorphic markers close to each telomere. Again no evidence for LOH of a particular chromosome arm was obtained, and no LOH was found in the genomic regions containing the NF2-related ERM family members ezrin and radixin, DAL-1, protein 4.1R, and TSLC1. Mutations in the X-chromosome based family member, moesin, were analysed by SSCP and were not detected. Microsatellite instability was studied using 6 commonly used markers but none of these was altered in any meningioma. Methylation was detected in 5 of 16 genes (NF2, p14(ARF), CDH1, BRCA1, RB1) previously shown to be silenced in a variety of tumour types. However, methylation percentages for these genes were generally higher in a group of NF2-related meningiomas, with the exception of the BRCA1 gene. The NF2 gene was methylated in only 1 of 21 tumours. In conclusion, meningiomas with an intact NF2 gene have a normal karyotype and no obvious genetic or epigenetic aberrations, suggesting that the gene(s) involved in the pathogenesis of these tumours are altered by smaller events than can be detected with the techniques used in our study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353169     DOI: 10.1002/path.1909

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

Review 1.  Pathological classification and molecular genetics of meningiomas.

Authors:  Christian Mawrin; Arie Perry
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

Review 2.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

3.  Meningioma of the cerebellopontine angle in identical twins: a case report.

Authors:  Shigeo Ohba; Kazunari Yoshida; Yuichi Hirose; Eiji Ikeda; Takeshi Kawase
Journal:  J Neurooncol       Date:  2009-12-13       Impact factor: 4.130

4.  Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Authors:  Mikołaj Łaniewski-Wołłk; Monika Gos; Andrzej Koziarski; Agnieszka Szpecht-Potocka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

5.  Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.

Authors:  Caisa M Hansson; Patrick G Buckley; Giedre Grigelioniene; Arkadiusz Piotrowski; Anders R Hellström; Kiran Mantripragada; Caroline Jarbo; Tiit Mathiesen; Jan P Dumanski
Journal:  BMC Genomics       Date:  2007-01-12       Impact factor: 3.969

Review 6.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

7.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

8.  Molecular biological determinations of meningioma progression and recurrence.

Authors:  Stefan Linsler; Dennis Kraemer; Christina Driess; Joachim Oertel; Kai Kammers; Jörg Rahnenführer; Ralf Ketter; Steffi Urbschat
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

9.  Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females.

Authors:  Agus Supartoto; Muhammad Bayu Sasongko; Datu Respatika; Indra Tri Mahayana; Suhardjo Pawiroranu; Hari Kusnanto; Dhimas Hari Sakti; Prima Sugesty Nurlaila; Didik Setyo Heriyanto; Sofia Mubarika Haryana
Journal:  Front Oncol       Date:  2019-01-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.